Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
(type err) |
(wlink todo) |
||
| Line 6: | Line 6: | ||
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | ||
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to [[carbazepine]]; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
Revision as of 19:32, 28 November 2016
S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]
Pharmacology
- Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
- Clinical utility of eslicarbazepine: current evidence
Mild inducers
After de Leon the following AED groups as mild inducers:
- clobazam
- eslicarbazepine
- rufinamide
- felbamate
- lamotrigine
- oxcarbazepine
- topiramate
- vigabatrin
- VPA
Cutaneous adverse effects
Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine
ATC code N03
Bioequivalence
References
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT
- ↑ The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AF04